Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$12.35 - $26.11 $225,967 - $477,734
18,297 Added 184.11%
28,235 $348,000
Q1 2024

Apr 25, 2024

BUY
$18.44 - $26.41 $167,527 - $239,934
9,085 Added 1065.06%
9,938 $201,000
Q4 2023

Feb 02, 2024

BUY
$12.64 - $30.11 $10,781 - $25,683
853 New
853 $19,000
Q2 2023

Aug 04, 2023

BUY
$21.59 - $27.88 $741,638 - $957,705
34,351 Added 780.7%
38,751 $950,000
Q1 2023

Apr 27, 2023

BUY
$23.46 - $36.44 $103,224 - $160,336
4,400 New
4,400 $106,000
Q3 2022

Nov 04, 2022

SELL
$16.33 - $51.06 $177,245 - $554,205
-10,854 Reduced 81.76%
2,422 $101,000
Q2 2022

Aug 03, 2022

BUY
$17.22 - $38.47 $124,586 - $278,330
7,235 Added 119.76%
13,276 $373,000
Q1 2022

May 02, 2022

BUY
$32.6 - $53.05 $188,721 - $307,106
5,789 Added 2297.22%
6,041 $224,000
Q4 2021

Feb 23, 2022

SELL
$36.77 - $90.91 $2.08 Million - $5.15 Million
-56,630 Reduced 99.56%
252 $11,000
Q3 2021

Oct 28, 2021

BUY
$41.79 - $135.3 $309,831 - $1 Million
7,414 Added 14.99%
56,882 $5.05 Million
Q2 2021

Aug 12, 2021

BUY
$32.15 - $89.72 $1.35 Million - $3.76 Million
41,855 Added 549.78%
49,468 $4.23 Million
Q1 2021

Apr 26, 2021

SELL
$7.09 - $87.95 $182,815 - $2.27 Million
-25,785 Reduced 77.21%
7,613 $342,000
Q4 2020

Feb 02, 2021

BUY
$6.79 - $12.25 $68,225 - $123,088
10,048 Added 43.03%
33,398 $0
Q3 2020

Oct 14, 2020

BUY
$2.86 - $11.51 $66,180 - $266,341
23,140 Added 11019.05%
23,350 $0
Q2 2020

Jul 13, 2020

SELL
$2.04 - $9.64 $81,316 - $384,260
-39,861 Reduced 99.48%
210 $0
Q1 2020

Apr 29, 2020

BUY
$3.26 - $9.65 $130,631 - $386,685
40,071 New
40,071 $164,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $95.4M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.